Ignite Creation Date:
2024-05-06 @ 12:16 AM
Last Modification Date:
2024-10-26 @ 10:47 AM
Study NCT ID:
NCT01533272
Status:
COMPLETED
Last Update Posted:
2015-04-01
First Post:
2012-02-08
Brief Title:
Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1FOVIREMTRICITABINA LOPINAVIRRITONAVIR VS TENOFOVIREMTRICITABINA MARAVIROC MARAVI-PEP
Sponsor:
Hospital Clinic of Barcelona
Organization:
Hospital Clinic of Barcelona
Study Overview
Official Title:
Open Randomized Study Comparing Two Alternatives of Antiretroviral Therapy as Post-exposure Prophylaxis to HIV-1 TENOFOVIREMTRICITABINA LOPINAVIRRITONAVIR VS TENOFOVIREMTRICITABINA MARAVIROC
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
As a measure of secondary prophylaxis and with the final objective of avoiding the infection it has been suggested to use antiretroviral therapy This is known as post-exposure prophylaxis PEP
Although there are different recommendations almost every guideline recommend using 3 drugs as PEP both in USA and Europe
Toxicity is one of the main limitations of PEP Side effects during PEP are very usual are attributed mainly to PI and are the main reasons for poor adherence or lost of follow-up
A current standard regimen is AZT3TC Combivir or tenofoviremtricitabine Truvada plus the PI lopinavirr Toxicity associated with this regimens are high 31-85 of cases with a 10-35 interruption of PEP Maraviroc a CCR5 receptor antagonist very well tolerated coul be an adequate drug for PEP
Although there are different recommendations almost every guideline recommend using 3 drugs as PEP both in USA and Europe
Toxicity is one of the main limitations of PEP Side effects during PEP are very usual are attributed mainly to PI and are the main reasons for poor adherence or lost of follow-up
A current standard regimen is AZT3TC Combivir or tenofoviremtricitabine Truvada plus the PI lopinavirr Toxicity associated with this regimens are high 31-85 of cases with a 10-35 interruption of PEP Maraviroc a CCR5 receptor antagonist very well tolerated coul be an adequate drug for PEP
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None